Long-term Effects of Natalizumab vs. Anti-CD20 Agents on PIRA in RRMS Patients
In a study with RRMS patients treated for at least five years, 27.0% of those on Natalizumab (NTZ) and 28.1% on anti-CD20 agents (Ocrelizumab, Rituximab, Ofatumumab) experienced a first PIRA event, with similar total rates of these events noted between the two groups (36 vs. 30). No significant differences in cumulative risk or time to first PIRA were found.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
This research suggests that NTZ and anti-CD20 therapies may provide comparable long-term control of disability progression in RRMS patients, beyond just relapse activity, which is essential for understanding treatment options.
What this does not prove
However, long-term comparative data on PIRA between NTZ and anti-CD20 agents is limited, and larger studies are needed to confirm these findings.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Yes
- Primary endpoint met
- No
- Relevant MS type
- RRMS
- Publication date
- Not reported
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceAnti-CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis. ↗DOI: 10.1111/ene.70771
Supporting passages (7)
controlledThe total number of PIRA events was comparable between NTZ-treated and anti-CD20-treated patients (36 vs.
primary endpoint metCONCLUSION: In this real-world cohort with long-term follow-up, NTZ and anti-CD20 therapies showed no significant differences in PIRA accrual or time to first PIRA, suggesting comparable long-term control of disability progression beyond relapse.
relevant ms typesMETHODS: We included RRMS patients followed at our centre and recorded in the Italian MS and Related Disorders Register with at least 5 years of continuous treatment with NTZ or anti-CD20 agents (Ocrelizumab, Rituximab, Ofatumumab), at least 3 Expanded Disability Status Scale (EDSS) assessments, and complete demographic and clinical data.
interventionMETHODS: We included RRMS patients followed at our centre and recorded in the Italian MS and Related Disorders Register with at least 5 years of continuous treatment with NTZ or anti-CD20 agents (Ocrelizumab, Rituximab, Ofatumumab), at least 3 Expanded Disability Status Scale (EDSS) assessments, and complete demographic and clinical data.
follow upMETHODS: We included RRMS patients followed at our centre and recorded in the Italian MS and Related Disorders Register with at least 5 years of continuous treatment with NTZ or anti-CD20 agents (Ocrelizumab, Rituximab, Ofatumumab), at least 3 Expanded Disability Status Scale (EDSS) assessments, and complete demographic and clinical data.
findingsThe total number of PIRA events was comparable between NTZ-treated and anti-CD20-treated patients (36 vs.
limitationsTitle: Anti-CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.